#USA #Houston #ASCO 2026 #Iterion Therapeutics #Tegavivint

Iterion Therapeutics Presents Phase 1/2 Data for Tegavivint at 2026 ASCO Meeting

In a landmark announcement, Iterion Therapeutics has revealed its latest findings regarding Tegavivint, a groundbreaking small-molecule inhibitor targeting cancers driven by Wnt/β-catenin signaling. This promising data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, scheduled from May 29 to June 2.

The Challenge of Advanced Hepatocellular Carcinoma

Advanced hepatocellular carcinoma (HCC) has become a significant global health challenge, being one of the leading causes of cancer-related deaths. Current treatment options are severely limited, especially for the approximately 50% of patients whose tumors exhibit activating mutations in the Wnt/β-catenin pathway. Thus, the introduction of targeted therapies like Tegavivint is critical in addressing this unmet medical need.

Innovative Mechanism of Action

Tegavivint functions by disrupting the TBL1-β-catenin transcriptional complex, promoting the degradation of nuclear β-catenin. This mechanism effectively inhibits oncogenic transcription, thereby showcasing significant potential in combating tumor growth in patients with advanced HCC. The importance of this approach was highlighted by Dr. Rahul Aras, President and CEO of Iterion Therapeutics, who emphasized the urgent need for such targeted treatments in the oncology landscape.

Presentation Highlights

The major presentation at ASCO will feature the Phase 1/2 dose-finding data in the rapid oral abstract session. Specific details are as follows:

• - Abstract #4015
• - Title: Tegavivint, a downstream Wnt/β-catenin inhibitor: Dose-finding results from a phase 1/2 trial in advanced hepatocellular carcinoma (aHCC)
• - Session: Rapid Oral Abstract Session - Gastrointestinal Cancer
• - Date/Time: June 1, 2026 | 1:15-2:45 PM CDT

Aside from the HCC data, the presentations will also include two important investigator-sponsored studies: one focusing on EGFR-mutated non-small cell lung cancer (NSCLC) and the other on relapsed or refractory pediatric osteosarcoma. These studies underline the versatility of Tegavivint and its applicability across various malignancies associated with Wnt-canonical signaling.

Recent Milestones

This announcement at ASCO follows several notable achievements for Iterion, including the initiation of patient dosing in clinical trials for metastatic colorectal cancer. Additionally, new preclinical data presented earlier this year at the AACR conference support the viability of TBL1 as an effective target for therapeutic intervention across Wnt-driven cancers.

About Iterion Therapeutics

Iterion Therapeutics actively focuses on pioneering first-in-class cancer therapies. Their strategy is primarily anchored on exploiting aberrant Wnt/β-catenin signaling to develop innovative treatments. With a committed team and funding amounting to $26 million from the Cancer Prevention and Research Institute of Texas (CPRIT), Iterion is evolving its research and development to address Wnt-driven cancers, positioning itself at the forefront of oncology treatment innovation.

For further details on Tegavivint and Iterion Therapeutics, visit their official website at www.iteriontherapeutics.com.